Premium
The future of neuroprotection in glaucoma therapeutics
Author(s) -
WHEELER LA
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2008.6446.x-i1
Subject(s) - memantine , neuroprotection , medicine , clinical trial , glaucoma , pharmacology , neuroscience , intensive care medicine , ophthalmology , psychology , dementia , disease
Purpose Give an overview on the future of neuroprotection in light of the announcements concerning the memantine phase 3 clinical trial. Methods Allergan recently unmasked the second memantine phase 3 clinical trial examining the efficacy and safety of oral memantine for the treatment of glaucoma. Results While the study failed to meet its primary endpoint to sufficiently replicate the results of the first phase 3 trial; additional data analyses are ongoing. What have we learned about studing neuroprotection in this pioneering effort? Conclusion An update on the status of the glutamate hypothesis and the implications for future neuroprotective therapies in glaucoma will be discussed.Commercial interest